carbapenemase-producing bacteria are a growing issue worldwide. Most phenotypic detection methods are culture-based, requiring long incubation times. We present a phenotypic screening panel for detection of carbapenem non-susceptibility and differentiation of carbapenemase classes and AmpC, the MALDI-TOF MS-based direct-on-target microdroplet growth assay (DOT-MGA). It was validated on 7 reference strains and 20 challenge Enterobacterales isolates. Broth microdilution (BMD) and combination disk test (CDT) were also performed, as well as PCR as reference method. The panel based on the synergy between meropenem and carbapenemase inhibitors, determined by incubating these substances with bacterial suspension on a MALDI-TOF MS target and subsequently assessing bacterial growth on the target's spots by MS. After 4 hours of incubation, DOT-MGA correctly identified KPC, MBL and OXA (100% agreement with PCR). Detection of AmpC coincided with BMD and CDT but agreement with PCR was low, not ruling out false negative PCR results. DOT-MGA delivered more accurate results than BMD and CDT in a significantly shorter time, allowing for detection of carbapenem non-susceptibility, MIC determination and carbapenemase differentiation in one step.The time to availability of microbiological results plays a critical role in the medical decision-making process as it has a direct impact on the choice of antimicrobial therapy. Advanced antimicrobial susceptibility testing (AST) methods may help to accelerate the targeted antimicrobial therapy 1 . However, the implications of a rapid and accurate laboratory diagnosis go beyond the clinical aspects: the consumption of antimicrobial substances as well as the rate of the development of bacterial resistance have shown to be directly affected by the information provided by the microbiology laboratory 2 . An association has also been observed between aspects concerning hospitalisation (amount of resources invested, total length of stay) and the accuracy of the implemented therapeutic strategies, which in turn depends on the turnaround times of the diagnostic tools employed 3-6 . Most importantly, a prompt detection of resistance patterns leads to better clinical outcomes 3,7,8 .Despite advances in phenotypic AST methodology, the time required for bacteria to replicate remained a natural obstacle, as reaching the stationary growth phase is required for the performance and interpretation of most available antibiotic susceptibility tests. This translates into incubation times exceeding 10 hours for culture-based